Molecular Devices LLC, a leader in protein and cell biology technologies, has announced a new, exciting brand for its recently created biologics solutions business unit. The business unit combines the industry leading ForteBio label-free technology platform with Molecular Devices’ Biologics Biotherapeutics portfolio of products, and henceforth will be known as ForteBio. It is accompanied by a new logo.
ForteBio’s mission is to fast-track timelines by removing hurdles in early stage biologics development through innovative technologies and workflow solutions. Its three core values aim to remove technical hurdles and workflow bottlenecks for its customers through best-in-class, high quality products and apply scientific expertise to solving customers’ research challenges through lasting partnerships.
“We are making great progress in hitting our milestones for the newly formed biologics business unit within Molecular Devices,” said Greg Milosevich, President of Molecular Devices. “We successfully defined our strategic plan earlier this summer aimed at taking market share in the fast growing early stage biologic drug R&D market and have assembled a strong commercial team to help us realize this goal. Our new brand identity and logo convey with great clarity our vision, mission and core values. With a refreshed brand, an energized team and new mission, I expect ForteBio will deliver important breakthroughs to power early stage biologic drug development.”